Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Glaucoma, particularly primary angle closure glaucoma (PACG), is a leading cause of global blindness. Nearly half of all people with PACG are of Chinese descent. Population-level glaucoma screening has generally not been found to be cost-effective in high-income countries; however, this assessment has rarely been done in low-income or middle-income countries. We aimed to assess the cost-effectiveness and cost-utility of population-level glaucoma screening in China. METHODS: We developed decision-analytic Markov models for separate and combined screening for PACG and primary open angle glaucoma (POAG) to evaluate costs and benefits of community-level screening versus opportunistic case finding from a societal perspective. A cohort of individuals was followed in the model from age 50 years through a total of 30 1-year Markov cycles. Analyses were done separately for rural and urban settings. We did a meta-analysis of glaucoma prevalence studies in China to obtain prevalence estimates for PACG and POAG. Screening costs were taken from a Chinese screening programme and treatment costs from a tertiary Chinese eye hospital. Main outcomes were incremental cost-utility ratios (ICURs) using quality-adjusted life-years and incremental cost-effectiveness ratios (ICERs) using years of blindness avoided. We did one-way deterministic and simulated probabilistic sensitivity analyses to reflect uncertainty around ICURs and ICERs. FINDINGS: Compared with no screening, combined screening of POAG and PACG in rural China is predicted to result in an ICUR of US$569 (95% CI 17 to 4180) and an ICER of $1280 (-58 to 7940), both of which are below the WHO cost-effectiveness threshold of one to three times rural gross domestic product. For the urban China setting, combined screening is predicted to result in fewer net costs and greater gain in health benefits than no screening. Findings were robust in all sensitivity analyses. Over 30 years, a total of 246 (95% CI 63 to 628) and 1325 (510 to 2828) years of blindness are predicted to be avoided for every 100 000 rural and urban residents screened, respectively. INTERPRETATION: Population screening for glaucoma (POAG and PACG combined) is likely to be cost-effective in both urban and rural China. Future studies should investigate the effectiveness of interventions to improve acceptance of definitive care among people screened. FUNDING: Ulverscroft Foundation, Wenzhou Medical University Research Fund, Zhejiang Province Health Innovation Talents Project, and Wenzhou's Ten Major Livelihood Issues 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
Tham, Y.-C., Li, X., Wong, T. Y., Quigley, H. A., Aung, T., & Cheng, C.-Y. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.013 · Cited by 7,159
The Pathophysiology and Treatment of Glaucoma: A Review
Weinreb, R. N., Aung, T., & Medeiros, F. A. (2014) · JAMA · doi:10.1001/jama.2014.3192 · Cited by 4,210
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., Loder, E., et al. (2013) · BMJ · doi:10.1136/bmj.f1049 · Cited by 1,776
Burden of Low Vision and Blindness in Chinese Elder Popullation:Data from Field Survey
Guan, X., Lin, F., Wang, L., Ni, Q., & Shi, L. (2016) · Value in Health · doi:10.1016/j.jval.2016.09.1267 · Cited by 7
Cited by
Liu, H., Li, R., Zhang, Y., Zhang, K., Yusufu, M., Liu, Y., Mou, D., Chen, X., Tian, J., Li, H., et al. (2023) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00554-x · Cited by 111
Self-citationCost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China
Huang, X.-M., Yang, B.-F., Zheng, W.-L., Liu, Q., Xiao, F., Ouyang, P.-W., Li, M.-J., Li, X.-Y., Meng, J., Zhang, T.-T., et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07655-6 · Cited by 89
“Blindness (in the following years) [34] 3,600 1,800–5,400”
Wang, Y., Liu, C., Hu, W., Luo, L., Shi, D., Zhang, J., Yin, Q., Zhang, L., Han, X., & He, M. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01032-9 · Cited by 76
Lin, S., Ma, Y., Xu, Y., Lu, L., He, J., Zhu, J., Peng, Y., Yu, T., Congdon, N., & Zou, H. (2023) · JMIR Public Health and Surveillance · doi:10.2196/41624 · Cited by 52
“…patients in the first year was estimated to be US $8920, which included 53.2% direct medical costs, 6.4% direct nonmedical costs, and 40.4% indirect costs (loss of labor resources for family members and low-vision services costs), and there were only indirect costs in the follow-up years [5,21].”
BackgroundMethodInfluentialSelf-citationHu, W., Joseph, S., Li, R., Woods, E., Sun, J., Shen, M., Jan, C. L., Zhu, Z., He, M., & Zhang, L. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102387 · Cited by 47
Metadata
- Authors
- Tang, J., Liang, Y., O'Neill, C., Kee, F., Jiang, J., & Congdon, N.
- Venue
- The Lancet Global Health
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 7
- Issue
- 7
- Pages
- e968-e978
- ISSN
- 2214-109X (ISSN-L)
- OpenAlex
- W2945844418
- Cited by
- 121
- References
- 5
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model. https://app.cochat.ai/papers/10.1016/s2214-109x(19)30201-3
- The paper
- Tang, J., Liang, Y., O'Neill, C., Kee, F., Jiang, J., & Congdon, N. (2019). Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(19)30201-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.